Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2677-2684

  McLeod, Howard L ^a   Cassidy, James ^a   Powrie, Robert H ^a   Priest, David G ^b   Zorbas, Mark A ^c   Synold, Timothy W ^d   Shibata, Stephen ^d   Spicer, Darcy ^e   Bissett, Donald ^a   Pithavala, Yazdi K ^c   Collier, Mary A ^c   Paradiso, Linda J ^c   Roberts, John D ^f  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ENZYME INHIBITION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; GLUTAMATES; GREAT BRITAIN; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PYRIMIDINES; REGRESSION ANALYSIS; UNITED STATES;

EID: 0033912002     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jackson, R. C., and Harkrader, R. J. The contributions of de novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. In: M. H. N. Tattersall and R. M. Fox (eds.), Nucleosides and Cancer Treatment, pp. 18-31. Sydney: Academic Press, 1981.
2. Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., and Mendelsohn, L. G. Novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res., 54: 1021-1026, 1994.
3. Ray, M. S., Muggia, F. M., Leichman, C. G., Grunberg, S. M., Nelson, R. L., Dyke, R. W., and Moran, R. G. Phase I study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J. Natl. Cancer Inst., 85: 1154-1159, 1993.
4. Sessa, C., deJong, Y., D'Incalci, M., Hatty, S., Pagani, O., and Cavalli, F. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin. Cancer Res., 2: 1123-1127, 1996.
5. Alati, T., Worzalla, J. F., Shih, C., Bewley, J. R., Lewis, S., Moran, R. G., and Grindey, G. B. Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res., 56: 2331-2335, 1996.
6. Muggia, F. M., Synold, T. W., Newman, E. M., Jeffers, S., Leichman, L. P., Doroshow, J. H., Johnson, K., and Groshen, S. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol. J. Natl. Cancer Inst., 88: 1495-1496, 1996.
7. Laohavinij, S., Wedge, S. R., Lind, M. J., Bailey, N., Humphrey, A., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Robson, L., Gumbrell, L., Taylor, G. A., Thomas, H. D., Boddy, A. V., Newell, D. R., and Calvert, A. H. A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest. New Drugs, 14: 325-335, 1996.
8. Roberts, J. D., Shibata, S., Spicer, D. V., McLeod, H. L., Tombes, M. B., Kyle, B., Carroll, M., Sheedy, B., Collier, M. A., Pithavala, Y. K., Paradiso, L. J., and Clendeninn, N. J. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every three weeks. Cancer Chemother. Pharmacol., 45: 423-427, 2000.
9. Bissett, D., McLeod, H. L., Sheedy, B., Collier, M., Pitsiladis, M., and Cassidy, J. Phase I and pharmacokinetic study of a novel folate analogue AG2034. Cancer Chemother. Pharmacol., in press, 2000.
10. Synold, T. W., Newman, E. M., Carroll, M., Muggia, F. M., Groshen, S., Johnson, K., and Doroshow, J. H. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin. Cancer Res., 4: 2349-2355, 1998.
11. Boritzki, T. J., Barlett, C. A., Zhang, C., Howland, E. E., Margosiak, S. A., Palmer, C. L., Romines, W. H., and Jackson, R. C. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest. New Drugs, 14: 295-303, 1996.
12. Zhang, C. C., Boritzki, T. J., and Jackson, R. C. An inhibitor of glycinamide ribonucleotide formyltransferase. Invest. New Drugs, 14: 295-303, 1996.
13. D'Argenio, D. Z. and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Prof. Biomed., 9: 115-134, 1979.
14. Vester, B., and Rasmussen, K. High-performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur. J. Clin. Chem. Clin. Biochem., 29: 549-554, 1991.
15. Marcell, P. D., Stabler, S. P., Podell, E. R., and Allen, R. H. Quantitation of methylmalonic acid and other dicarboxylic acids in normal serum and urine using capillary gas chromatography mass spectrometry. Ann. Biochem., 150: 58-66, 1985.
16. Priest, D. G., Schmitz, J. C., Bunni, M. A., and Stuart, R. K. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J. Natl. Cancer Inst., 83: 1806-1812, 1991.
17. Wedge, S. R., Laohavinij, S., Taylor, G. A., Boddy, A., Calvert, A. H., and Newell, D. R. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10,dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin. Cancer Res., 1: 1479-1486, 1995.
18. Masson, E., Relling, M. V., Synold, T. W., Liu, Q., Schuetz, J. D., Sandlund, J. T., Pui, C. H., and Evans, W. E. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo - a rationale for high-dose methotrexate. J. Clin. Invest., 97: 73-80, 1996.
19. Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., and Pui, C. H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med., 338: 499-505, 1998.
20. Jansen, G., Barr, H., Kathmann, I., Bunni, M. A., Priest, D. G., Noordhuis, P., Peters, G. J., and Assaraf, Y. G. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol. Pharmacol., 55: 761-769, 1999.